Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Mr. Joseph P. Hagan M.B.A. |
IPO Date | Oct. 4, 2012 |
Location | United States |
Headquarters | 4224 Campus Point Court, San Diego, CA, United States, 92121 |
Employees | 30 |
Sector | Healthcare |
Industry | Biotechnology |
Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
NA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email